Call 2-1-1 for local resources · Life-threatening emergencies: 9-1-1
Back to education guides

Substance education guide

Carisoprodol (Soma)

Centrally acting skeletal muscle relaxant · Carbamate derivative · Schedule IV

· How it works

Classification and primary mechanism

Carisoprodol is a centrally acting skeletal muscle relaxant and prodrug. The liver converts much of it through CYP2C19 into meprobamate, a sedative that enhances GABA-A receptor inhibition and can produce profound central nervous system depression at high doses. Carisoprodol begins acting in about 30 minutes; meprobamate lasts substantially longer, allowing accumulation with repeated dosing.

· Immediate effects

Recognize the effects

Signs of Use

  • Drowsiness, dizziness, slowed responses, or poor coordination
  • Slurred speech, confusion, disinhibition, or unusual behavior
  • Muscle weakness, tremors, or high-dose involuntary twitching
  • Nausea, headache, blurred vision, or faintness
  • Slow, shallow, or irregular breathing in severe poisoning

Short Term

  • Short-term relief of painful acute musculoskeletal conditions when prescribed
  • Sedation, impaired driving, reduced attention, and loss of coordination
  • Euphoria or disinhibition when misused or taken at high doses
  • Respiratory depression, coma, or death when combined with other depressants

Long Term

  • Tolerance, cravings, and carisoprodol or meprobamate dependence
  • Withdrawal with anxiety, insomnia, tremors, hallucinations, or seizures
  • Accumulation of the long-lived meprobamate metabolite with repeated dosing
  • Injury risk from impaired balance, driving, or decision-making

· Long-term consequences

Dangerous interactions

Never combine carisoprodol with opioids, benzodiazepines, alcohol, gabapentin, pregabalin, sleep medicines, or other sedatives unless a clinician specifically directs it. Combining central nervous system depressants can suppress breathing and cause fatal overdose.

Back to education guides